---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-000579"
form_type: "8-K"
ticker: "COLL"
cik: "0001267565"
company_name: "COLLEGIUM PHARMACEUTICAL, INC"
filed_at: "2024-01-03T23:59:59+00:00"
generated_at: "2026-06-07T04:31:35.663956+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Collegium 2024 guidance: revenue $580-595M, adj. EBITDA $380-395M, $150M buyback

## Summary
- FY2024 product revenue net expected $580M-$595M; adjusted EBITDA $380M-$395M.
- Board authorized $150M share repurchase program through June 30, 2025.
- Xtampza ER gross-to-net improving to 56%-58% after renegotiations covering 30% of scripts.
- Belbuca renegotiated major Medicare Part D contract, reducing rebate, and won new plan (~1M lives).
- Returned $75M to shareholders in 2023 under prior buyback, including $25M accelerated repurchase.

## SEC filing metadata
- accession: 0001104659-24-000579
- form_type: 8-K
- ticker: COLL
- cik: 0001267565
- company_name: COLLEGIUM PHARMACEUTICAL, INC
- filed_at: 2024-01-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1267565/000110465924000579/0001104659-24-000579-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1267565/000110465924000579/tm241446d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-000579
- JSON: https://secwatch.observer/filing/0001104659-24-000579.json
- Plain text: https://secwatch.observer/filing/0001104659-24-000579.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.